This blog critically analyzes the potential scientific limitations,
risks and liabilities of cell based reporter assays, including non-
natural protein based reporter assays (e.g. circularly permuted
firefly luciferase or GFP based reporter assays) and stem cell based
assays, in drug discovery and development. Scientific arguments have
been put forward to suggest that current format of cell based reporter
assays may not be ideal for replacing animal studies. This blog also
analyzes the potential negative impact of patents and intellectual
property (IP) rights in fostering innovations in cell based assays.
Finally, this blog warrants imposing accountability, tighter
regulations and demanding higher standards in cell based assays that
are used in drug discovery and development. Please follow this link to
read the full blog article:
http://sciclips.wordpress.com/2012/01/16/cell-based-reporter-assays-vs-animal-studies-in-drug-discovery-potential-limitations-risks-and-liabilities/
